High Dose Chemotherapy and Autologous Transplant for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00186641
Recruitment Status : Unknown
Verified July 2007 by Stanford University.
Recruitment status was:  Active, not recruiting
First Posted : September 16, 2005
Last Update Posted : July 11, 2007
Information provided by:
Stanford University

Brief Summary:
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Condition or disease Intervention/treatment Phase
Graft vs Host Disease Procedure: high dose chemo and auto hematopoietic cell transplant Phase 2

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer
Study Completion Date : March 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage II, III or IV breast cancer
  • chemosensitive
  • adequate organ function

Exclusion Criteria:

  • prior transplant,
  • life threatening disease
  • brain metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00186641

United States, California
Stanford University Cancer Center
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Ginna Laport, MD Stanford University Identifier: NCT00186641     History of Changes
Other Study ID Numbers: BMT42
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: July 11, 2007
Last Verified: July 2007

Keywords provided by Stanford University:
chronic Graft vs Host Disease

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases